Anti-Human CD221 (Insulin-like Growth Factor-1 Receptor) APC

Description: This 1H7 monoclonal antibody reacts with human insulin-like growth factor-1 receptor (IGF-1R), also known as CD221. This receptor is a cell surface-expressed glycoprotein composed of two extracellular alpha subunits and two transmembrane beta subunits that possess tyrosine kinase activity. Expressed on nearly all cell types, this receptor binds IGF-I and IGF-II, as well as insulin. Ligand binding leads to activation of the PI3K/Akt and MAPK pathways, which mediate cell proliferation and survival. Many tumors and transformed cells display altered IGF-1R expression.

This monoclonal antibody has been reported to block binding of IGF-I and IGF-II to the IGF-1R.

References: Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res. 2008 Oct 15;14(20):6364-70. Review.

Li SL, Kato J, Paz IB, Kasuya J, Fujita-Yamaguchi Y. Two new monoclonal antibodies against the alpha subunit of the human insulin-like growth factor-I receptor. Biochem Biophys Res Commun. 1993 Oct 15;196(1):92-8. (1H7, WB)

Reiss K, Porcu P, Sell C, Pietrzkowski Z, Baserga R. The insulin-like growth factor 1 receptor is required for the proliferation of hemopoietic cells. Oncogene. 1992 Nov;7(11):2243-8.